key: cord-0802730-roxbzj7t
authors: Godbole, Ira; Ciminski, Kevin; Yousefi, O. Sascha; Pathan-Chhatbar, Salma; Saltukoglu, Deniz; Vesper, Niklas; Salavei, Pavel; Strietz, Juliane; Gensch, Nicole; Reth, Michael; Schwemmle, Martin; Schamel, Wolfgang W.
title: Engineered chimeric T cell receptor fusion construct (TRuC)-expressing T cells prevent translational shutdown in SARS-CoV-2-infected cells
date: 2021-06-25
journal: bioRxiv
DOI: 10.1101/2021.06.25.449871
sha: 433c44d93a9c417fdede4fec2b3dd8cd7a4d3917
doc_id: 802730
cord_uid: roxbzj7t

SARS-CoV-2, the causative agent of Covid-19, is known to evade the immune system by several mechanisms. This includes the shutdown of the host cellular protein synthesis, which abrogates the induction of antiviral interferon responses. The virus initiates the infection of susceptible cells by binding with its spike protein (S) to the host angiotensin-converting enzyme 2 (ACE2). Here we applied the T cell receptor fusion construct (TRuC) technology to engineer T cells against such infected cells. In our TRuCs an S-binding domain is fused to the CD3ε component of the T cell receptor (TCR) complex, enabling recognition of S-containing cells in an HLA independent manner. This domain either consists of the S-binding part of ACE2 or a single-chain variable fragment of an anti-S antibody. We show that the TRuC T cells are activated by and kill cells that express S of SARS-CoV-2 and its alpha (B.1.1.7) and beta (B.1.351) variants at the cell surface. Treatment of SARS-CoV-2 infected cells with our engineered T cells did not lead to massive cytotoxicity towards the infected cells, but resulted in a complete rescue of the translational shutdown despite ongoing viral replication. Our data show that engineered TRuC T cell products might be used against SARS-CoV-2 by exposing infected cells to the host innate immune system.

. Alternatively, in the absence of TMPRSS2, the 57 virion is endocytosed and S cleavage as well as membrane fusion takes place in endosomes 58 (Hoffmann et al., 2020; Simmons et al., 2005) . 59

One of the major innate antiviral defence mechanisms is the type I interferon (IFN-I) system, 60 the induction of which stimulates the expression of a large number of interferon-stimulated 61 genes (ISGs). In case of coronaviruses the viral RNA is sensed by retinoic acid-inducible gene 62 the non-structural protein 1 (Nsp1) inhibits nuclear export of host mRNA, but also blocks 70 ribosomal translation by binding to the 40S ribosomal subunit (Kamitani et instead of only the isolated cytoplasmic tail of CD3ζ. One such example are chimeric 101 receptors called TCR fusion constructs (TRuCs). The TCR itself is a complicated multiprotein 102 machine composed of the antigen-binding TCRαβ subunits and the signal transduction 103

CD3εγ, CD3εδ and ζζ subunits. Ligand-binding leads to the exposure of signaling motifs in 104 the cytoplasmic tails of CD3, such as a proline-rich sequence, basic-rich sequences, the 105 receptor-kinase motif and the immuno-tyrosine based activation motifs (ITAMs) (Hartl et al., 106 2020; Reth, 1989; Schamel et al., 2019) . These conformational changes, the recruitment of 107 signaling molecules to the motifs and phosphorylation of the ITAMs are delicately controlled 108 to determine the quantity and quality of the signal, eventually leading to the activation and 109 differentiation of the T cell in a proper way. Importantly, mechanisms also control that in the 110 absence of ligand the TCR is held in a closed, inactive conformation (Swamy, Schamel JI) . 

To re-program T cells to recognize SARS-CoV-2-infected cells, we here constructed εTRuCs 129 able to bind the SARS-CoV-2 S protein. To this end, the S-binding part of the extracellular 130 domain of human ACE2 (aa 18-615) (Yan et al., 2020) was genetically fused to human CD3ε 131 in a lentiviral vector. A short or a long linker were used to connect the two proteins, resulting 132 in ACE2s-εTRuC and ACE2l-εTRuC ( Fig. 1A fused to CD3ε, yielding the αS-εTRuC ( Fig. 1A and B) ; the linker that was used before to 136 construct the αCD19-εTRuC (Baeuerle et al., 2019) was chosen. All lentiviruses also encode 137 for GFP fused with a T2A peptide to the εTRuC. 138

Jurkat T cells that lack CD3ε do not express a TCR on their surface (Fig. 1C, untransduced) . 139

When they were lentivirally transduced with the S-specific εTRuCs, a TCR containing these 140 εTRuCs was expressed on the surface as seen by anti-CD3, anti-ACE2 and anti-IgG staining 141 ( Fig. 1C , D, E, S1). As controls, we used lentiviruses that only encode for GFP (mock) or for 142 the αCD19-εTRuC. Co-purification of the endogenous TCR subunits TCRβ and CD3ζ with 143 the εTRuCs demonstrates that the εTRuCs assemble into a TCR (Fig. 1F ). Since CD3ζ is the 144 last subunit to be added during TCR assembly (De Waal Malefyt et al., 1989; Minami et al., 145 1987) , the data shows that the εTRuCs integrated into full TCRs. The Western blot confirmed 146 the expected sizes of the εTRuCs (Fig. 1F) . Hence, the SARS-CoV-2-specific εTRuCs are 147 expressed as part of a TCR on the surface of Jurkat T cells. 148

To test whether this binding would lead to T cell activation, we used human Ramos-null B 149 cells (with a deletion of the B cell receptor (He et al., 2018) ) expressing SARS-CoV-2 S on 150 their surface ( Fig. 2A and S2A ). These cells could activate our S-specific εTRuC-expressing 151

Jurkat cells as seen by upregulation of the activation marker CD69 ( Fig. 2B and S2B) . 

Next, expanded primary human T cells were transduced to express the εTRuCs, in order to 165 test for the cytotoxic capability of these T cells. All εTRuCs were expressed well on the 166 surface of the T cells (Fig. 3A) , which were CD8 + and CD4 + T cells (Suppl. Fig. S3A ). 167

As an example to look at target cell killing, we chose the αS-εTRuC T cells which were co-168 cultured with Ramos cells that express a chimeric SARS-CoV-2 S protein with a C-terminal 169 (cytosolic) fusion to the red fluorescent protein mScarlet (S-mScarlet, Fig. 3B ). Hence, 170 transduced T cells (green) can be distinguished from the target cells (red) by confocal 171 fluorescent imaging (Fig. 3C ). After contact of the αS-εTRuC T cells with the S-expressing 172

Ramos cells, a stable cell conjugate was formed that lasted on average 153 min (Fig. 3 D) . 173

Most likely an immunological synapse was formed as seen by the polarisation of the 174 lysosomes (stained in magenta) towards the target cells (Fig. 3C , upper row, second image). 175

In most cases, the S-expressing Ramos cells were killed as detected by membrane blebbing 176 (upper row, last image) that is typical for apoptosis. When the target cell was killed, this took 177 on average 121 min (Fig. 3E) . As a control, both mock transduced T cells and untransduced T 178 cells, had only short contact to the Ramos cells (average 10 min) and left without cytotoxic 179 activity ( Fig. 3C and D) . 180

All S-specific εTRuC and control engineered primary T cells were co-cultured with the 181

Ramos cells, which served as target cells, expressing or not the SARS-CoV-2 S, to quantify 182 the cytotoxic activity. The target cells also expressed the firefly luciferase and BFP (Suppl. 183 Fig 2C) . If they were lysed, luciferase activity was lost, serving as a readout for the killing of expressing S from HCoV-NL63, -OC43 or -229E (Fig. 3F ). There was a weak, but clear, 189 activity also against Ramos cells expressing S from SARS-CoV-1. As above, we did not 190 observe any differences between the ACE2l-, ACE2s-and αS-εTRuCs. Together these data 191 demonstrate that we were able to redirect primary T cells to kill efficiently target cells that variants. The ones from SARS-CoV-1 and HCoV-NL63 caused a slight CD69 upregulation, 199 whereas the ones from HCoV-OC43 or -229E were inactive. In the T cells that are not 200 specific for the SARS-CoV-2 S, CD69 was not upregulated by any S-expressing Ramos cell 201 (Fig. 4A) . We also show that the engineered T cells that were activated by SARS-CoV-2 S-202 expressing target cells secreted the cytokines IL2, IFNγ, IFNα and TNFα (Fig. 4B) . As a 203 control, the mock T cells did not produce any of those cytokines nor did a co-culture with 204

Ramos cells that do not express any S (Fig. S4A ). In conclusion, our re-programmed T cells 205 with the new S-specific εTRuCs could be activated by S-expressing target cells. 206 207

Having shown that the S-specific εTRuC T cells kill S-expressing Ramos cells, we wanted to 209 test whether these TRuC T cells are also able to kill SARS-CoV-2-infected Vero E6 cells 210 

Next, we repeated the treatment of infected VeroLucBFP cells with our T cells, but recording 

The loss of luciferase activity at later time points post infection, which is indicative for the 272 translation shutdown, was drastically reduced upon S-specific εTRuC T cell treatment ( Lastly, we sought to get insight into how the S-specific εTRuC T cell blocks the virus-287 induced translation shutdown. To this end, we activated ACE2s-or αS-εTRuC T cells by co-288 culturing them with S-expressing Ramos cells for 24 hours. We then collected the medium 289 that should contain factors that these T cells secrete and treated uninfected and SARS-CoV-2-290 infected VeroLucBFP cells with this "conditioned" medium. Upon treatment of SARS-CoV-291 2-infected cells with the ACE2s-or αS-εTRuC T cell "conditioned" medium, the loss of 292 luciferase activity and of BFP expression was reduced compared to cells incubated with 293 "conditioned" medium derived from mock T cells ( Fig. 7A and 7B) . These data suggest that were also killed efficiently, suggesting that these currently circulating variants of concern 323 might be equally well targeted by our εTRuCs. Importantly, while escape from neutralising 324 antibody binding is frequently observed for SARS-CoV-2 variants (Hoffmann et al., 2021) , 325 the reliance on ACE2-mediated entry into the host cells by SARS-CoV-2 suggests that escape 326 from binding to ACE2-εTRuC will impose an unlikely strong fitness cost. Ramos cells 327 expressing S from SARS-CoV-1 and HCoV-NL63 were recognized to a certain degree, since 328 S of these viruses also binds to ACE2, albeit with lower affinity ( The plasmids used in this study were generated using standard molecular cloning techniques, 407 such as PCR, restriction digest and Gibson assembly (Gibson et al., 2009) 

For the molecular cloning of the pHRSIN-CS-Luc-IRES-mTagBFP2 vector, the previously 424 Fisher, #31402), and HRPO-coupled anti-rabbit IgG (Thermo Fisher, #31460). Protein G-497 coupled sepharose (#17-0618-01) and Protein A-coupled sepharose (#17-5138-01) beads 498 were from GE Healthcare and the protease inhibitor cocktail was from Sigma. 499 3 × 10 7 cells were lysed in 0.4 ml lysis buffer containing 20 mM Tris-HCl pH8, 137 mM 500 NaCl, 2 mM EDTA, 10% glycerol, 1x protease inhibitor cocktail, 1 mM PMSF, 5 mM 501 iodoacetamide, 0.5 mM sodium orthovanadate, 1 mM NaF, and 0.5% Brij96 for 30 min at 502 4 °C followed by 15 min centrifugation to pellet the nuclei and insoluble material. For the 503 anti-CD3ε immunoprecipitation 370 μl cleared cell lysate was incubated with 5 μl 50% 504 protein A and protein G sepharose slurry (1:1) and 2 μg anti-CD3ε UCHT1 for 4 h at 4 °C. 505

After three washes, the immunoprecipitated material was separated by 12% reducing SDS-506 PAGE. The separated proteins were transferred to PVDF membranes by semi-dry transfer. 507

After blocking with 5% milk in PBS containing 0.1% Tween-20 the membranes were 508 

A bioluminescence based cytotoxicity assay was performed with transduced primary cells co-559 cultured with VeroE6 (kidney epithelial cells extracted from an African green monkey), Cells were stained with an anti-CD3 antibody and measured by flow cytometry (n>3). D and E, The cells from C were stained with anti-ACE2 and anti-IgG antibodies. The mean fluorescence intensity (MFI) of triplicates is shown (the experiment was repeated more than 3 times, n>3). F, The cells from C were lysed and TCRs immunopurified using an anti-CD3 antibody. After reducing SDS-PAGE, the CD3ε, TCRβ and CD3ζ subunits were visualized by Western blotting (n=3). Fig. 2 The new εTRuCs re-program Jurkat cells to recognize S-expressing cells. A, By binding to the S-specific εTRuCs, Ramos cells expressing S activate the εTRuC Jurkat cells. B, Ramos cells without S and those expressing SARS-CoV-2 S were co-cultured with the Jurkat CD3εKO transductants from A and stained with anti-CD69 antibodies. After flow cytometric measurement, T cells were gated and the percentage of CD69-positive cells of triplicates is shown (the experiment was repeated more than 3 times, n>3).

A, Primary human T cells were transduced with the lentiviral vectors encoding for the εTRuCs or the mock vector and expanded with IL-2. Surface expression of the εTRuCs was determined by anti-Fab, anti-ACE2 and anti-IgG staining as indicated. B, S-and luciferaseexpressing Ramos cells are killed by the new εTRuC T cells. C, An αS-εTRuC T cell (green) with the lysosomes stained in pink and an S-mScarlet-expressing Ramos cell (red) were imaged and selected frames of the given times are shown (upper panel). Non-transduced (middle panel) and mock-transduced (green, lower panel) T cells were imaged together with the S-mScarlet-expressing Ramos cells (red). D, Quantification of the duration of interaction between S-mScarlet-expressing Ramos cells and αS-εTRuC or mock T cells from the 4 h videos. E, Quantification of the time it takes for an αS-εTRuC T cell to kill an S-mScarletexpressing Ramos cell (the purple lines in D and E depict the median). F, Ramos cells expressing luciferase, BFP and the different S-proteins were co-cultured with the εTRuC T cells for 24 h at in a 1:1 ratio. Target cell lysis was measured by a loss of luciferase activity in triplicates (the experiment was repeated more than 3 times, n>3). A, The Jurkat CD3εKO transductants as indicated were stained with an anti-CD3 antibody and measured by flow cytometry. The MFI of the CD3 stain is shown. This is a quantification of triplicates, as shown in figure 1C . B, The cells from A were stained with an anti-ACE2, anti-IgG, or anti-Fab antibody and measured by flow cytometry (the experiment was performed more than three times, n>3). These are some of the original data that were used to generate figures 1D and 1E. These data show that the αCD19-, ACE2s-, ACE2l-and the αS-εTRuC are expressed on the surface of Jurkat CD3εKO cells.

A, Ramos cells expressing the S of the corona viruses as indicated and GFP were lentivirally transduced to bicistronically express firefly luciferase and BFP. The flow cytometric plots show the GFP and BFP fluorescence intensity (the experiment was performed more than three times, n>3). This data demonstrates that the Ramos cells express both the S and luciferase. B, Ramos cells without S and those expressing SARS-CoV-2 S were co-cultured for 9 h with the Jurkat CD3εKO cells expressing the εTRuCs as indicated, being transduced with the GFPexpressing mock vector or left untransduced. Subsequently, cells were stained with anti-CD69 and anti-CD3 antibodies and analysed by flow cytometry. These original data were used to generate figure 2C.

The S-specific εTRuCs are expressed on CD4 + and CD8 + T cells. A, At day 5 after mock or εTRuC transduction the primary, IL2-expanded T cells were stained with anti-CD4, anti-CD8 and the εTRuC-specific antibodies as in figure 3A . As an example, the anti-CD4 and anti-CD8 stain is shown for the mock transduction. B, The ratio of CD8 to CD4 cells, of the untransduced or transduced primary T cells is shown from the data as in A. C, The percentage of CD8 + TRuC + (left panel) and CD4 + TRuC + (right panel) cells are shown from the data as in A (n>3). These data show that the εTRuC expression did not alter the ratio of CD8 + to CD4 + T cells.

A, Secretion of cytokines by the εTRuC T cells following co-culture with the Ramos cells not expressing SARS-CoV-2 S was quantified by ELISA in triplicates (n=3). This was done in parallel to data shown in figure 4B and demonstrates that the engineered T cells are specifically activated by cells expressing S. virus and treated with mock transduced, αCD19-εTRuC, ACE2s-εTRuC, ACE2l-εTRuC, and αS-εTRuC expressing primary T cells in the ratio of 1:1, i.e., one transduced T cell was added per VeroE6 cell. B, The negative control is the treatment of Vero E6 cells without infection but treatment with mock, αCD19-εTRuC, ACE2s-εTRuC, ACE2l-εTRuC, and αS-εTRuC primary T cells in 1:1 ratio. C, CacoLucBFP cells infected with SARS-CoV-2 virus (MOI 0.05) were treated with mock, αCD19-εTRuC, ACE2s-εTRuC, ACE2l-εTRuC, and αS-εTRuC primary cells in the ratio of 3:1, i.e., three transduced T cells were added per target cell. D, The negative control for is the treatment of CacoLucBFP cells without infection but treatment with mock, αCD19-εTRuC, ACE2s-εTRuC, ACE2l-εTRuC, and αS-εTRuC primary T cells in 3:1 ratio. E, CaluLucBFP cells infected with SARS-CoV-2 virus (MOI 0.05) were treated with mock, αCD19-εTRuC, ACE2s-εTRuC, ACE2l-εTRuC, and αS-εTRuC primary cells in the ratio of 3:1, i.e., three transduced T cells were added per target cell. F, The negative control for Fig S6E is the treatment of Calu-3 cells without infection but treatment with mock, αCD19-εTRuC, ACE2s-εTRuC, ACE2l-εTRuC, and αS-εTRuC primary cells in 3:1 ratio. The data demonstrate that at low MOI the initial killing of infected cells cannot be detected, but the prevention of a partial translational shutdown took place.

Strategies to Address Chimeric Antigen Receptor Tonic 629 Signaling

Synthetic TRuC receptors 632 engaging the complete T cell receptor for potent anti-tumor response

SARS-CoV-2 Disrupts Splicing

Translation, and Protein Trafficking to Suppress Host Defenses

NLRC5 promotes transcription of 638 BTN3A1-3 genes and Vγ9Vδ2 T cell-mediated killing

Introduction of T cell receptor (TCR)-alpha cDNA has 641 differential effects on TCR-gamma delta/CD3 expression by PEER and Lyon-1 cells

Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. 645

Cytokine Release Syndrome 648

After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

Identification of chimeric 652 antigen receptors that mediate constitutive or inducible proliferation of T cells

Enzymatic assembly of DNA molecules up to several hundred kilobases

Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential 659 for T cell receptor signaling and synapse formation

How Can We Engineer CAR T Cells 661 to Overcome Resistance?

Targets of T Cell 664 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed 665 Individuals

Emerging Cellular Therapies for Cancer

Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte

Immunobiology and pathogenesis of viral 672 hepatitis

Implications of T cell receptor biology on the development of new T cell therapies for cancer. 675 Immunother

Noncanonical 678 binding of Lck to CD3ε promotes TCR signaling and CAR function

Continuous signaling of CD79b and CD19 is required for the 682 fitness of Burkitt lymphoma B cells

SARS-CoV-2 variants B.1.351 685 and P.1 escape from neutralizing antibodies

SARS-CoV-2 Cell Entry 688 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus 692 receptor for cellular entry

Flow 695 cytometry multiplexed method for the detection of neutralizing human antibodies to the native 696 SARS-CoV-2 spike protein

Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 699 protein

The 701

Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon 702 Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination

Direct observation 705 of ligand recognition by T cells

A 707 two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein

Structure of the SARS-CoV-2 Spike receptor-binding domain bound to the 711 ACE2 receptor

Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human 714 ribosome inhibits translation initiation

Rapid response flow cytometric assay 717 for the detection of antibody responses to SARS-CoV-2

Activation and evasion of type I interferon responses by SARS-CoV-2

Chimeric STAR receptors using TCR machinery mediate robust 724 responses against solid tumors

CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-727 2-infected Cells

Efficacy of Targeting SARS-CoV-2 by 729 CAR-NK Cells

Internalization and cycling of 731 the T cell antigen receptor. Role of protein kinase C

Full 733 activation of the T cell receptor requires both clustering and conformational changes at CD3. 734 Immunity

Cytokine release 736 syndrome and associated neurotoxicity in cancer immunotherapy

Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene 740 expression, including that of type I interferon, in infected cells

Virus Isolation from the First Patient with 743 SARS-CoV-2 in Korea

Inhibitors of ribosome functions

The translational landscape of SARS-747

CoV-2 and infected cells

T cell killing does not 749 require the formation of a stable mature immunological synapse

Engineering strategies to overcome 751 the current roadblocks in CAR T cell therapy

CAR-and TRuC-redirected regulatory T cells differ in capacity to control 754 adaptive immunity to FVIII

Antigen receptor tail clue

Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and 759 Disease Severity

The TCR is an allosterically 761 regulated macromolecular machinery changing its conformation while working

Synthetic immune signaling

Characterization of pre-existing and 767 induced SARS-CoV-2-specific CD8+ T cells

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus 770 entry

Intracellular detection of viral nucleic acids

Allostery Model of T Cell Receptor Phosphorylation

Severe 777 acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through 778 a specific translational shutoff of host mRNA

Human 781 monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape 782 mutants

Structural basis for 785 translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

Potent binding of 2019 novel coronavirus spike protein by a SARS 789 coronavirus-specific human monoclonal antibody

Cryo-EM structure of the 2019-nCoV spike in the prefusion 792 conformation

Crystal structure of NL63 respiratory 794 coronavirus receptor-bindingdomain complexed with its human receptor

Evasion of Type I Interferon by SARS-CoV-2

Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to 800 Bind With Human ACE2

A novel antibody-TCR (AbTCR) platform combines Fab-803 based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity 804 with low cytokine release

Structural basis for the 806 recognition of SARS-CoV-2 by full-length human ACE2

Human aminopeptidase N is a receptor for human 809 coronavirus 229E

A highly conserved cryptic epitope in the receptor binding domains of SARS-812

Nonstructural Protein 1 of SARS-CoV-2 Is a Potent 815

Pathogenicity Factor Redirecting Host Protein Synthesis Machinery toward Viral RNA

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as 819 potent interferon antagonists

Nsp1 protein of SARS-CoV-2 disrupts the mRNA export 822 machinery to inhibit host gene expression

Elevated exhaustion levels and reduced functional diversity of T 825 cells in peripheral blood may predict severe progression in COVID-19 patients

A pneumonia outbreak associated with a new coronavirus of 829 probable bat origin